Authors
1 Faculty of Allied Health Sciences KuwaitnMedical Laboratory Sciences
2 Department of biology, Tehran-east branch, Islamic azad university, Tehran, Iran
3 Personalized Medicine Research Center of AmitisGen, Tehran, Iran
Abstract
Although several techniques have been developed for the detection of JAK2 V617F mutation, these techniques have their disadvantages. High-resolution melting (HRM) analysis is a new, post-PCR analysis. Simple and fast, this method is based on PCR melting curve techniques. This study examined the JAK2 V617F mutation by the high-resolution melting method in 20 patients with erythrocytosis, and the results were compared with those obtained from the direct sequencing method. The results showed 100% sensitivity and 100% positive predictive value for this methodology in the patient sample set tested.
Keywords
- Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative diseases. Lancet 2005;365:1054–61.
- Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofi brosis. Cancer Cell 2005;7:387–97.
- Vainchenker W, Constantinescu SN. A unique activating mutation in JAK2(V617F) is at the origin of polycythemia vera and allows a new classifi cation of myeloproliferative diseases. Hematology 2005;2005:195–200.
- Zhao R, Xing S, Li Z, et al. Identifi cation of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005;280:22788–92.
- James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature 2005;434:1144–8.
- Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779–90.
- Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005;106:2162–8.
- Kr¨oger N, Badbaran A, Holler E, et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofi brosis. Blood 2007;109:1316–21.
- Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofi brosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092–7.
- Vardiman JW, Bennett JM, Bain BJ, et al. Myelodysplastic/myeloproliferative neoplasm, unclassifi able. In: Swerdlow SH, Campo E, Harris NL, et al, editors. WHO classifi cation of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. p. 85–6.
- Lippert E, Boissinot M, Kralovics R, et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 2006;108:1865–7.
- Steensma DP. JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 2006;8:397–411.
- Wittwer CT, Reed GH, Gundry CN, Vandersteen JG, Pryor RJ. High-resolution genotyping by amplicon melting analysis using LCGreen. Clin Chem 2003;49: 853–60.
- Herrmann MG, Durtschi JD, Bromley LK, Wittwer CT, Voelkerding KV. Amplicon DNA melting analysis for mutation scanning and genotyping: cross-platform comparison of instruments and dyes. Clin Chem 2006;52:494–503.
- Pola´kova´ KM, Lopotova´ T, Klamova´ H, Moravcova´ J. High Resolution melt curve analysis: initial screening for mutations in BCR-ABL kinase domain. Leuk Res 2008;32:1236–43.
- van der Stoep N, van Paridon CD, et al. Diagnostic guidelines for highresolution melting curve (HRM) analysis: an interlaboratory validation of BRCA1 mutation scanning using the 96-well LightScanner. Hum Mutat 2009;30:899–909.
)